Fig. 1From: A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancerPFS in a all patients, b patients without visceral involvement, and c patients with visceral involvement. Data are from phase II part. CI, confidence interval; HR, hazard ratio; n.c., not calculable; PFS, progression-free survivalBack to article page